|
🐜
|
C3 glomerulopathy: consensus report
35 auth.
M. Pickering,
V. D’Agati,
C. Nester,
Richard J. H. Smith,
M. Haas,
G. Appel,
C. Alpers,
I. Bajema,
C. Bedrosian,
M. Braun,
M. Doyle,
F. Fakhouri,
F. Fervenza,
A. Fogo,
V. Frémeaux-Bacchi,
...
D. Gale,
E. Goicoechea de Jorge,
G. Griffin,
C. Harris,
V. Holers,
Sally Johnson,
P. Lavin,
N. Medjeral-Thomas,
B. Paul Morgan,
C. Nast,
L. Noel,
D. Peters,
S. Rodríguez de Córdoba,
A. Servais,
S. Sethi,
W. Song,
P. Tamburini,
J. Thurman,
M. Zavros,
H. Cook
|
9 |
2013 |
9
🐜
|
|
🐜
|
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
18 auth.
C. Licht,
L. Greenbaum,
P. Muus,
S. Babu,
C. Bedrosian,
D. Cohen,
Yahsou Delmas,
K. Douglas,
R. Furman,
O. Gaber,
...
T. Goodship,
M. Herthelius,
M. Hourmant,
C. Legendre,
G. Remuzzi,
N. Sheerin,
A. Trivelli,
C. Loirat
|
8 |
2015 |
8
🐜
|
|
🐜
|
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
15 auth.
M. Mita,
A. Mita,
Q. Chu,
E. Rowinsky,
G. Fetterly,
M. Goldston,
A. Patnaik,
L. Mathews,
A. Ricart,
T. Mays,
...
H. Knowles,
V. Rivera,
J. Kreisberg,
C. Bedrosian,
A. Tolcher
|
8 |
2008 |
8
🐜
|
|
🐢
|
Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
F. Fakhouri,
J. Campistol,
J. Menne,
E. Minetti,
E. Rondeau,
C. Bedrosian
|
8 |
2016 |
8
🐢
|
|
🐜
|
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
15 auth.
L. Greenbaum,
M. Fila,
G. Ardissino,
S. Al-Akash,
J. Evans,
P. Henning,
K. Lieberman,
S. Maringhini,
L. Pape,
L. Rees,
...
N. C. van de Kar,
J. Vande Walle,
M. Ogawa,
C. Bedrosian,
C. Licht
|
7 |
2016 |
7
🐜
|
|
🐜
|
Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters.
16 auth.
S. Sonis,
S. Sonis,
R. Peterson,
L. Edwards,
C. Lucey,
Lu Wang,
L. Mason,
G. Login,
G. Login,
M. Ymamkawa,
...
G. Moses,
G. Moses,
P. Bouchard,
L. Hayes,
C. Bedrosian,
A. Dorner
|
7 |
2000 |
7
🐜
|
|
🐜
|
A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
10 auth.
D. Rizzieri,
E. Feldman,
J. Dipersio,
N. Gabrail,
W. Stock,
R. Strair,
...
V. Rivera,
M. Albitar,
C. Bedrosian,
F. Giles
|
7 |
2008 |
7
🐜
|
|
🐜
|
Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry
13 auth.
H. Schrezenmeier,
P. Muus,
G. Socié,
J. Szer,
Á. Urbano-Ispizua,
J. Maciejewski,
R. Brodsky,
M. Bessler,
Y. Kanakura,
W. Rosse,
...
G. Khursigara,
C. Bedrosian,
P. Hillmen
|
7 |
2014 |
7
🐜
|
|
🐜
|
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.
8 auth.
R. Cofiell,
A. Kukreja,
Krystin A. Bedard,
Yan Yan,
Angela P. Mickle,
M. Ogawa,
...
C. Bedrosian,
S. Faas
|
7 |
2015 |
7
🐜
|
|
🐜
|
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis
10 auth.
G. Socié,
Marie-Pierre Caby-Tosi,
J. Marantz,
A. Cole,
C. Bedrosian,
C. Gasteyger,
...
A. Mujeebuddin,
P. Hillmen,
J. Vande Walle,
H. Haller
|
7 |
2019 |
7
🐜
|
|
🐜
|
Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants.
18 auth.
A. Rapoport,
L. M. Miller Watelet,
Tammy Linder,
S. Eberly,
R. Raubertas,
Joanna Lipp,
R. Duerst,
C. Abboud,
L. Constine,
Jessica Andrews,
...
M. Etter,
Linda Spear,
Elizabeth Powley,
C. Packman,
J. Rowe,
U. Schwertschlag,
C. Bedrosian,
J. Liesveld
|
7 |
1999 |
7
🐜
|
